Yonghua Li1, Fengqi Duan2, Haowen Xiao1, Xiaoxiong Wu3, Shunqing Wang4, Duorong Xu5, Qifa Liu6, Zhiping Fan6, Danian Nie7, Yongrong Lai8, Bingyi Wu9, Dongjun Lin10, Xin Du11,12, Jianyu Weng11, Zujun Jiang1, Yan Pang1, Ling Ouyang1, Zenghui Liu1, Leqin Zhang1, Na Han2, Lixuan Chen2, Yang Xiao2,13. 1. Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, China. 2. Southern Medical University, Guangzhou, China. 3. The First Affiliated Hospital to Chinese PLA General Hospital, Beijing, China. 4. Guangzhou First People's Hospital, Guangzhou, China. 5. The First Affiliated Hospital of Zhongshan University, Guangzhou, China. 6. Nanfang Hospital, Southern Medical University, Guangzhou, China. 7. Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. 8. The First Affiliated Hospital of Guangxi medical university, NanNing, China. 9. Zhujiang Hospital of Sourthern Medical University, Guangzhou, China. 10. Third Hospital of Sun Yat-Sen University, Guangzhou, China. 11. Guangdong General Hospital, Guangzhou, China. 12. Shenzhen Second People Hospital, Shenzhen, China. 13. Stem Cell Translational Medicine Center, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Abstract
BACKGROUND: Haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (HSCT) is an alternative curative treatment for patients with severe aplastic anemia (SAA) who do not have suitable matched related donors (MRD). The aim of this study was to compare the therapeutic outcomes of HID-HSCT with those of MRD-HSCT for SAA. METHODS: A total of 235 SAA patients who underwent HID-HSCT (116) or MRD-HSCT (119) at 11 transplantation centers from January 2007 to January 2016 were included. Complications and survival outcomes were evaluated and compared between the 2 groups. RESULTS: The HID group had a lower incidence of secondary graft failure but higher incidences of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). However, the incidence of severe aGVHD (grades III-IV), poor graft function, and infections was comparable between groups. Patients in the HID group had a significantly lower survival and overall survival rates than those in the MRD group. The estimated 3-year survival rates for the MRD and HID groups were 82.82% and 75.00%, respectively. Ferritin levels, graft failure, poor graft function, severe aGVHD, and infections were the significant risk factors for survival. CONCLUSIONS: The overall survival rate is acceptable for patients who underwent HID-HSCT, making it a feasible treatment choice for SAA patients.
BACKGROUND: Haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (HSCT) is an alternative curative treatment for patients with severe aplastic anemia (SAA) who do not have suitable matched related donors (MRD). The aim of this study was to compare the therapeutic outcomes of HID-HSCT with those of MRD-HSCT for SAA. METHODS: A total of 235 SAApatients who underwent HID-HSCT (116) or MRD-HSCT (119) at 11 transplantation centers from January 2007 to January 2016 were included. Complications and survival outcomes were evaluated and compared between the 2 groups. RESULTS: The HID group had a lower incidence of secondary graft failure but higher incidences of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). However, the incidence of severe aGVHD (grades III-IV), poor graft function, and infections was comparable between groups. Patients in the HID group had a significantly lower survival and overall survival rates than those in the MRD group. The estimated 3-year survival rates for the MRD and HID groups were 82.82% and 75.00%, respectively. Ferritin levels, graft failure, poor graft function, severe aGVHD, and infections were the significant risk factors for survival. CONCLUSIONS: The overall survival rate is acceptable for patients who underwent HID-HSCT, making it a feasible treatment choice for SAApatients.
Authors: Raheel Iftikhar; Parvez Ahmad; Regis de Latour; Carlo Dufour; Antonio Risitano; Naeem Chaudhri; Ali Bazarbachi; Josu De La Fuente; Britta Höchsmann; Syed Osman Ahmed; Usama Gergis; Alaa Elhaddad; Constantijn Halkes; Bassim Albeirouti; Sultan Alotaibi; Austin Kulasekararaj; Hazzaa Alzahrani; Tarek Ben Othman; Simone Cesaro; Ali Alahmari; Rawad Rihani; Salem Alshemmari; Amir Ali Hamidieh; Mohamed-Amine Bekadja; Jakob Passweg; Murtadha Al-Khabori; Walid Rasheed; Andrea Bacigalupo; Qamar-Un-Nisa Chaudhry; Per Ljungman; Judith Marsh; Riad El Fakih; Mahmoud Aljurf Journal: Bone Marrow Transplant Date: 2021-05-19 Impact factor: 5.483